Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
Year: 2020
Type: review
Abstract: OBJECTIVE: Assess achievement of low-density lipoprotein cholesterol (LDL-C) targets in European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. DESIGN: Systematic literature review. DATA SOURCES: Medline, EMBASE, Cumulated Index to Nursing and Allied Health Literature. ELIGIBILITY CRITERIA: Observational studies reporting LDL-C levels/target attainment, measured between 1 August 2006 to 31 August 2017, in European adults with established cardiovascular disease (CVD), diabetes with target organ damage, familial hypercholesterolaemia (FH) or 10-year risk of fatal CVD ≥ 5% (assessed by Systematic Coronary Risk Evaluation [SCORE]). DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted relevant studies and assessed study quality using the Risk of Bias for Non-Randomised Studies-Interventions (ROBINS-I) tool. Primary outcome was the proportion of patients achieving LDL-C targets in the 2011/2016 ESC/EAS guidelines. Where available, patient characteristics were presented as means weighted by sample size. The proportions of patients achieving LDL-C targets in the 5 years before and after publication of the 2011 guidelines were compared using a chi-square test. RESULTS: Across 81 eligible studies (303,534 patients), achievement of LDL-C < 1.8 mmol/L was poor among patients with established CVD (16%; range 9-56%) and at very high risk of CVD (SCORE ≥ 10% [18%; 14-25%]). In individuals with FH, SCORE 5-10%, or diabetes and target organ damage, LDL-C < 2.5 mmol/L was achieved by 15% (9-22%), 46% (21-55%) and 13% (6-34%), respectively. Comparing the 5 years before/after publication of the 2011 guidelines, target achievement increased significantly over time but remained suboptimal (LDL-C < 1.8, 22% versus 15%; LDL-C < 2.5, 68% versus 61%; both p < 0.001; established CVD group only). CONCLUSIONS: These data show suboptimal LDL-C control among European patients at high risk of CVD. Those at greatest overall risk (clinically established CVD or at least a 10% 10-year risk of fatal CVD) had the lowest achievement of 2011/2016 EAS/ESC LDL-C targets. With lower LDL-C targets advocated in 2019 ESC/EAS guidelines, this unmet need will increase. PROTOCOL REGISTRATION: PROSPERO registration number; CRD77844.
Source: Advances in Therapy
Institutions: Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Unité de recherche sur les maladies cardiovasculaires et métaboliques, Fondation pour l’innovation en Cadiométabolisme et Nutrition, LMU Klinikum, Ludwig-Maximilians-Universität München, Universidade de Santiago de Compostela, Centro de Investigación en Red en Enfermedades Cardiovasculares, Complejo Hospitalario Universitario de Santiago, University of Copenhagen, Herlev Hospital, Copenhagen University Hospital, Gentofte Hospital, IT University of Copenhagen, Sapienza University of Rome, Amgen (Switzerland), Imperial College London
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: LDL cholesterol, LDL-C goal attainment, high-risk patients, very high-risk patients, cardiovascular disease, familial hypercholesterolemia, ESC/EAS guidelines, guideline implementation, statin therapy, Europe, cardiovascular risk stratification, cardiovascular mortality, cardiovascular hospitalization
Open Access status: hybrid
Estimated APC paid: $3,860
Funder: Amgen
OpenAlex ID: W3011818146
